| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.CCA.2006.05.010 |
| P698 | PubMed publication ID | 16784736 |
| P50 | author | Zhao-Qian Liu | Q69033386 |
| P2093 | author name string | Qing Li | |
| Wei Zhang | |||
| An Wang | |||
| Hong-Hao Zhou | |||
| Lan Fan | |||
| Yi-Jing He | |||
| Zhi-Rong Tan | |||
| Ya-Li Liu | |||
| Bang-Ning Yu | |||
| Fen-Jiang | |||
| Yuan-Fei Huang | |||
| P433 | issue | 1-2 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 99-103 | |
| P577 | publication date | 2006-11-01 | |
| P1433 | published in | Clinica Chimica Acta | Q5133740 |
| P1476 | title | Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males | |
| P478 | volume | 373 |
| Q92960175 | 3D structure of the transporter ABCG2-What's new? |
| Q35617587 | A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics? |
| Q37050337 | A perspective on efflux transport proteins in the liver |
| Q38107993 | ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. |
| Q43174441 | ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin |
| Q45993642 | ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. |
| Q46294694 | ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans |
| Q60916021 | ATP-Binding Cassette Transporters in the Clinical Implementation of Pharmacogenetics |
| Q36597410 | ATP-binding cassette, subfamily G (ABCG family). |
| Q39486373 | Acyclovir is a substrate for the human breast cancer resistance protein (BCRP/ABCG2): implications for renal tubular transport and acyclovir-induced nephrotoxicity |
| Q36593505 | BCRP/ABCG2 in the placenta: expression, function and regulation |
| Q33704930 | Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe |
| Q90613746 | Cellular Processing of the ABCG2 Transporter-Potential Effects on Gout and Drug Metabolism |
| Q38160088 | Clinical impact of genetic variants of drug transporters in different ethnic groups within and across regions |
| Q43109279 | Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population |
| Q36796490 | Current Perspectives on rosuvastatin |
| Q34702620 | Decreased hepatic breast cancer resistance protein expression and function in multidrug resistance-associated protein 2-deficient (TR⁻) rats |
| Q92435676 | Development of precision medicine approaches based on inter-individual variability of BCRP/ABCG2 |
| Q43258273 | Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin |
| Q90814739 | Dose-Dependent Inhibition of OATP1B by Rifampicin in Healthy Volunteers: Comprehensive Evaluation of Candidate Biomarkers and OATP1B Probe Drugs |
| Q37793056 | Drug transport by breast cancer resistance protein. |
| Q38177333 | Drug-drug interaction with statins. |
| Q39985485 | Dyslipidemia in Special Ethnic Populations |
| Q35573543 | Dyslipidemia in special ethnic populations |
| Q54006194 | Effect of CYP2C19 polymorphism on the pharmacokinetics of rosuvastatin in healthy Taiwanese subjects. |
| Q89690229 | Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug-Drug Interaction Studies |
| Q33686542 | Effect of epigallocatechin-3-gallate, major ingredient of green tea, on the pharmacokinetics of rosuvastatin in healthy volunteers |
| Q51266635 | Effect of polymorphisms in CYP3A4, PPARA, NR1I2, NFKB1, ABCG2 and SLCO1B1 on the pharmacokinetics of lovastatin in healthy Chinese volunteers. |
| Q37371551 | Effect of pregnancy on nitrofurantoin disposition in mice |
| Q40018547 | Effect of silymarin supplement on the pharmacokinetics of rosuvastatin |
| Q38071700 | Effect of the ATP-binding cassette transporter ABCG2 on pharmacokinetics: experimental findings and clinical implications |
| Q46062183 | Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients |
| Q37724381 | Efflux and uptake transporters as determinants of statin response. |
| Q35183649 | Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers |
| Q33433942 | Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer |
| Q38084901 | Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism |
| Q44737065 | Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans |
| Q38155218 | Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin |
| Q48811919 | Evaluation of the usefulness of breast cancer resistance protein (BCRP) knockout mice and BCRP inhibitor-treated monkeys to estimate the clinical impact of BCRP modulation on the pharmacokinetics of BCRP substrates. |
| Q37790379 | Fetoprotective activity of breast cancer resistance protein (BCRP, ABCG2): expression and function throughout pregnancy |
| Q57110508 | Gene-by-Environment Interaction of Bcrp-/- and MCD Diet-Induced Nonalcoholic Steatohepatitis Alters SN-38 Disposition |
| Q48893219 | Generation and Characterization of a Breast Cancer Resistance Protein Humanized Mouse Model. |
| Q37481450 | Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs |
| Q34292537 | Genetic variation in drug transporters in ethnic populations |
| Q37331801 | Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes |
| Q37331821 | Hepatic basolateral efflux contributes significantly to rosuvastatin disposition II: characterization of hepatic elimination by basolateral, biliary, and metabolic clearance pathways in rat isolated perfused liver. |
| Q38560889 | Hepatic drug transporters: the journey so far. |
| Q53611791 | Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect? |
| Q85432136 | Impact of Menopause on Pharmacokinetics of Rosuvastatin Compared with Premenopausal Women |
| Q38888369 | Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant? |
| Q38888365 | Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites |
| Q42933358 | Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia |
| Q92132562 | Influence of OATP1B1 and BCRP polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects |
| Q36687277 | Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans |
| Q39034284 | Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1). |
| Q38379295 | Intestinal and hepatic drug transporters: pharmacokinetic, pathophysiological, and pharmacogenetic roles |
| Q37339515 | Investigation of the Bioequivalence of Rosuvastatin 20 mg Tablets after a Single Oral Administration in Mediterranean Arabs Using a Validated LC-MS/MS Method |
| Q28570070 | Knocking down breast cancer resistance protein (Bcrp) by adenoviral vector-mediated RNA interference (RNAi) in sandwich-cultured rat hepatocytes: a novel tool to assess the contribution of Bcrp to drug biliary excretion |
| Q38129422 | Lipid-lowing pharmacogenomics in Chinese patients |
| Q34897883 | Membrane topology of the human breast cancer resistance protein (BCRP/ABCG2) determined by epitope insertion and immunofluorescence |
| Q29616802 | Membrane transporters in drug development |
| Q89372273 | No effects of pantoprazole on the pharmacokinetics of rosuvastatin in healthy subjects |
| Q57500318 | Organic anion transporting polypeptide-1B1 haplotypes in Chinese patients |
| Q28068014 | Pediatric Statin Administration: Navigating a Frontier with Limited Data |
| Q37182212 | PhRMA white paper on ADME pharmacogenomics. |
| Q46826559 | Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans |
| Q37074291 | Pharmacogenetics of response to statins |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q37235629 | Pharmacogenomic importance of ABCG2. |
| Q38112823 | Pharmacogenomics of lipid-lowering therapies |
| Q88061446 | Pharmacokinetic study of rosuvastatin in males and females |
| Q42562160 | Pharmacokinetics of rosuvastatin in 30 healthy Zimbabwean individuals of African ancestry |
| Q58073610 | Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective |
| Q38243832 | Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance |
| Q39773424 | Quantitative Analyses of Hepatic OATP-Mediated Interactions Between Statins and Inhibitors Using PBPK Modeling With a Parameter Optimization Method |
| Q30244632 | Racial Differences in the Cholesterol-Lowering Effect of Statin |
| Q39140289 | Renal Drug Transporters and Drug Interactions |
| Q34774854 | Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance |
| Q46109720 | Reverse Translational Research of ABCG2 (BCRP) in Human Disease and Drug Response |
| Q34871636 | Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update |
| Q46204648 | Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions. |
| Q41512597 | Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States |
| Q34579035 | SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers |
| Q41737190 | Safety and pharmacokinetics of the CIME combination of drugs and their metabolites after a single oral dosing in healthy volunteers. |
| Q89642081 | Simvastatin intolerance genetic determinants: some features in ethnic Uzbek patients with coronary artery disease |
| Q53417201 | Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP. |
| Q38207943 | Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics |
| Q40359311 | Subtle Structural Differences Trigger Inhibitory Activity of Propafenone Analogues at the Two Polyspecific ABC Transporters: P-Glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP). |
| Q34035243 | Sulindac and its metabolites inhibit multiple transport proteins in rat and human hepatocytes. |
| Q36803379 | The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects. |
| Q37810986 | The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins |
| Q53736039 | The Effect of Genetic Polymorphisms in SLCO2B1 on the Lipid-Lowering Efficacy of Rosuvastatin in Healthy Adults with Elevated Low-Density Lipoprotein. |
| Q42151027 | The effect of ABCG2 V12M, Q141K and Q126X, known functional variants in vitro, on the disposition of lamivudine |
| Q43003337 | The effect of acute administration of rifampicin and imatinib on the enterohepatic transport of rosuvastatin in vivo |
| Q81241502 | The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1 |
| Q38303543 | The identification of two germ-line mutations in the human breast cancer resistance protein gene that result in the expression of a low/non-functional protein |
| Q50868889 | The influence of CYP3A5*3 and BCRPC421A genetic polymorphisms on the pharmacokinetics of felodipine in healthy Chinese volunteers. |
| Q34613443 | The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. |
| Q34079760 | The influence of herbal medicine ursolic acid on the uptake of rosuvastatin mediated by OATP1B1*1a and *5. |
| Q37537018 | The role of transporters in the pharmacokinetics of orally administered drugs |
| Q37862942 | Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase |
| Q35927508 | Three-dimensional structure of the human breast cancer resistance protein (BCRP/ABCG2) in an inward-facing conformation |
| Q46766214 | Understanding the Potential Interethnic Difference in Rosuvastatin Pharmacokinetics |
| Q88118125 | Using Physiologically Based Pharmacokinetic (PBPK) Modeling to Evaluate the Impact of Pharmaceutical Excipients on Oral Drug Absorption: Sensitivity Analyses |
| Q33714593 | Xenobiotic, bile acid, and cholesterol transporters: function and regulation. |
Search more.